Samuel Reed
Amministratore Delegato presso DNAe Group Holdings Ltd.
Profilo
Samuel Reed currently works at DNAe Group Holdings Ltd., as Chief Executive Officer & Director.
Posizioni attive di Samuel Reed
Società | Posizione | Inizio |
---|---|---|
DNAe Group Holdings Ltd.
DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
DNAe Group Holdings Ltd.
DNAe Group Holdings Ltd. Medical SpecialtiesHealth Technology Part of Genting Bhd., DNAe Group Holdings Ltd. is a healthcare company based in London, UK. DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications, including infectious disease and cancer testing and monitoring. The British company is developing Lidia-seq™, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide actionable information to clinicians. DNAe's initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The company's major shareholder is Genting Berhad, a Malaysian-based investor with a growing portfolio of investments in cutting-edge life sciences companies. The company was founded in 2003 by Christofer Toumazou. The CEO is Samuel Reed. | Health Technology |
- Borsa valori
- Insiders
- Samuel Reed